1
|
Bu J, Pang S, Kong X, Liu B, Xiao Q, Qu C. Investigation of mediastinal lymph node dissection in clinical stage IA pure-solid non-small cell lung cancer patients. J Cardiothorac Surg 2024; 19:357. [PMID: 38910251 PMCID: PMC11194863 DOI: 10.1186/s13019-024-02839-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 06/14/2024] [Indexed: 06/25/2024] Open
Abstract
OBJECTIVE To explore the independent predictors of pathological mediastinal lymph node (pN2) metastasis in clinical stage IA (cIA) pure-solid non-small cell lung cancer (NSCLC) patients, and to find an appropriate method of mediastinal lymph node dissection. METHODS This study retrospectively evaluated 533 cIA pure-solid NSCLC patients who underwent radical resection of lung cancer (lobectomy combined with systematic lymph node dissection) from January 2014 to December 2016. The relationship between clinicopathological characteristics and pN2 metastasis was analyzed, and the independent predictors of pN2 metastasis were determined by univariate and multivariate logistic regression analysis. We defined the new factor Y as composed of preoperative cT, CEA, and NSE. RESULTS There were 72 cases (13.5%) of pN2 metastasis in cIA pure-solid NSCLC patients. Preoperative clinical tumor diameter (cT), serum CEA level, serum NSE level, and pathological status of station 10 lymph nodes were independent predictors of pN2 metastasis. Patients with cT ≤ 21.5 mm, CEA ≤ 3.85 ng/mL, NSE ≤ 13.40 ng/mL and negative station 10 lymph node group showed lower rates of pN2 metastasis. The new factor Y was an independent predictor of pN2 metastasis. Only 3 (2.1%) of 143 patients in the Y low-risk group showed pN2 metastasis. CONCLUSION For patients with low risk of pN2 metastasis, it might be feasible to take lobe-specific lymph node sampling or systematic lymph node sampling. As for those with high risk of pN2 metastasis, systematic lymph node dissection would be recommended.
Collapse
Affiliation(s)
- Jianlong Bu
- Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, No.150, Haping Rd., Nangang District, Harbin, Heilongjiang Province, 150081, China
| | - Sainan Pang
- Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, No.150, Haping Rd., Nangang District, Harbin, Heilongjiang Province, 150081, China
| | - Xianglong Kong
- Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, No.150, Haping Rd., Nangang District, Harbin, Heilongjiang Province, 150081, China
| | - Benkun Liu
- Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, No.150, Haping Rd., Nangang District, Harbin, Heilongjiang Province, 150081, China
| | - Qifan Xiao
- Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, No.150, Haping Rd., Nangang District, Harbin, Heilongjiang Province, 150081, China
| | - Changfa Qu
- Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, No.150, Haping Rd., Nangang District, Harbin, Heilongjiang Province, 150081, China.
| |
Collapse
|
2
|
Manfredini B, Zirafa CC, Filosso PL, Stefani A, Romano G, Davini F, Melfi F. The Role of Lymphadenectomy in Early-Stage NSCLC. Cancers (Basel) 2023; 15:3735. [PMID: 37509396 PMCID: PMC10378311 DOI: 10.3390/cancers15143735] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 07/18/2023] [Accepted: 07/21/2023] [Indexed: 07/30/2023] Open
Abstract
Lung cancer remains the leading cause of cancer-related death worldwide. The involvement of lymph nodes by the tumor has a strong impact on survival of patients. For this reason, lymphadenectomy plays a crucial role in the staging and prognosis of NSCLC, to define the most appropriate therapeutic strategies concerning the stage of the disease. To date, the benefit, in terms of survival, of the different extents of lymphadenectomy remains controversial in the scientific community. It is recognized that metastatic involvement of mediastinal lymph nodes in lung cancer is one of the most significant prognostic factors, in terms of survival, and it is therefore mandatory to identify patients with lymph node metastases who may benefit from adjuvant therapies, to prevent distant disease and local recurrences. The purpose of this review is to evaluate the role of lymphadenectomy in early-stage NSCLC in terms of efficacy and accuracy, comparing systematic, sampling, and lobe-specific lymph node dissection and analyzing the existing critical issue, through a search of the most relevant articles published in the last decades.
Collapse
Affiliation(s)
- Beatrice Manfredini
- Division of Thoracic Surgery, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy
| | - Carmelina Cristina Zirafa
- Minimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy
| | - Pier Luigi Filosso
- Division of Thoracic Surgery, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy
| | - Alessandro Stefani
- Division of Thoracic Surgery, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy
| | - Gaetano Romano
- Minimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy
| | - Federico Davini
- Minimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy
| | - Franca Melfi
- Minimally Invasive and Robotic Thoracic Surgery, Surgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy
| |
Collapse
|
3
|
Chiappetta M, Leuzzi G, Sperduti I, Bria E, Mucilli F, Lococo F, Spaggiari L, Ratto GB, Filosso PL, Facciolo F. Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis†. Eur J Cardiothorac Surg 2020; 55:405-412. [PMID: 30202953 DOI: 10.1093/ejcts/ezy311] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2018] [Revised: 07/27/2018] [Accepted: 08/07/2018] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES The prognostic role of the number of resected and metastatic lymph nodes in non-small-cell lung cancer (NSCLC) is still being debated. The aim of this study was to evaluate the impact of lymphadenectomy in addition to the already validated variables in NSCLC survival. METHODS From January 2002 to December 2012, data on 4858 patients with NSCLC undergoing anatomical lung resection and hilomediastinal lymphadenectomy in 6 institutions were analysed retrospectively. Established prognostic factors in addition to the number of resected lymph nodes and the ratio between the number of metastatic lymph nodes and the number of resected lymph nodes (NR) were correlated to overall survival (OS) and disease-free survival (DFS) using the multivariable Cox regression model. Harrell's C-statistic with the 95% confidence interval (CI) was determined. Analysis by means of maximally selected log-rank statistics was performed to find optimal cut-off points in order to split patients into groups with different outcome probabilities. RESULTS The median numbers of resected lymph nodes and of metastatic lymph nodes were 17 (range 6-85) and 2 (1-36), respectively. Hilar (N1) and mediastinal (N2) metastases were identified in 21.3% and 20.0% of cases, respectively. Overall, the 5-year OS and DFS rates were 54.6% and 44.8%, respectively. At multivariable analysis, age, gender, pathological stage, R0 resection, type of surgery and NR correlated with longer OS rates; the same variables plus tumour grading were further related to DFS. C-statistics were 66.0 (95% CI 62.7-69.4) for DFS and 60.5 (95% CI 58.3-62.6) for OS. An NR <40% significantly correlated with a higher 5-year survival rate in the total sample (OS 57.6% vs 23.8%, P < 0.001; DFS 48.2% vs 11.4, P < 0.001) and in patients with N1 (OS 47.9% vs 36.1%, P = 0.03; DFS 39% vs 24.2%, P = 0.02) and N2 (OS 36.9% vs 21.8%, P < 0.001 DFS 23.9% vs 9.1%, P < 0.001). CONCLUSIONS Our study confirms that the number of resected lymph nodes is a strong prognostic indicator in NSCLC. In particular, an NR cut-off value of 40% may predict both OS and DFS.
Collapse
Affiliation(s)
- Marco Chiappetta
- Thoracic Surgery, Regina Elena National Cancer Institute - IFO, Rome, Italy.,Università Cattolica del Sacro Cuore, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
| | - Giovanni Leuzzi
- Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | | | - Emilio Bria
- Università Cattolica del Sacro Cuore, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.,Medical Oncology- Università Cattolica del Sacro Cuore, Department of Medicine, University Hospital of Verona, Verona, Italy
| | - Felice Mucilli
- Department of General and Thoracic Surgery, University Hospital "SS. Annunziata", Chieti, Italy
| | - Filippo Lococo
- Unit of Thoracic Surgery, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
| | - Lorenzo Spaggiari
- Thoracic Surgery Division, European Institute of Oncology, University of Milan, Milan, Italy
| | | | - Pier Luigi Filosso
- Department of Thoracic Surgery, University of Turin, San Giovanni Battista Hospital, Turin, Italy
| | - Francesco Facciolo
- Thoracic Surgery, Regina Elena National Cancer Institute - IFO, Rome, Italy
| |
Collapse
|
4
|
Lu Y, Ma T, Wang L, Xue T. [Advances in Lymph Node Metastasis and Lymph Node Dissection
in Early Non-small Cell Lung Cancer]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2020; 22:520-525. [PMID: 31451143 PMCID: PMC6717872 DOI: 10.3779/j.issn.1009-3419.2019.08.07] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
肺癌是目前我国发病率和死亡率均居首位的恶性肿瘤,其中以非小细胞肺癌为主要病理类型。淋巴结转移是非小细胞肺癌最常见和最主要的转移途径,也是影响肺癌分期和预后最重要的因素。由于目前通过现有手段术前很难准确判断早期非小细胞肺癌患者的淋巴结受累情况。因此,在早期非小细胞肺癌中,尤其是在临床Ⅰ期非小细胞肺癌患者中,淋巴结清扫方式一直存在很大争议。本文就非小细胞肺癌淋巴结转移的规律及清扫方式进行综述。
Collapse
Affiliation(s)
- Yun Lu
- Department of Cardiothoracic Surgery, the Affiliated Zhongda Hospital of Southeast University, Nanjing 210000, China
| | - Teng Ma
- Department of Cardiothoracic Surgery, the Affiliated Zhongda Hospital of Southeast University, Nanjing 210000, China
| | - Lei Wang
- Department of Cardiothoracic Surgery, the Affiliated Zhongda Hospital of Southeast University, Nanjing 210000, China
| | - Tao Xue
- Department of Cardiothoracic Surgery, the Affiliated Zhongda Hospital of Southeast University, Nanjing 210000, China
| |
Collapse
|
5
|
Liu X, Xu S, Liu B, Xu W, Ding R, Wang T, Li B, Wang X, Wu Q, Teng H, Wang S. [Survival Analysis of Stage I Non-small Cell Lung Cancer Patients Treated with
Da Vinci Robot-assisted Thoracic Surgery]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2018; 21:849-856. [PMID: 30454547 PMCID: PMC6247004 DOI: 10.3779/j.issn.1009-3419.2018.11.07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
背景与目的 达芬奇机器人手术系统在胸外科的应用日益广泛,本研究旨在探讨经达芬奇机器人手术治疗Ⅰ期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的疗效。 方法 回顾2012年1月-2017年12月于我科行手术治疗的Ⅰ期NSCLC患者347例,依据手术方式分为机器人(robot-assisted thoracic surgery, RATS)组134例及腔镜(video-assisted thoracic surgery, VATS)组213例。比较两组患者围术期一般指标(术中出血量、术后引流量、术后带管时间、术后住院时间、淋巴结清扫状况),分析患者生存状况(overall survival, OS)、无进展生存状况(disease free survival, DFS)及相关影响因子。 结果 机器人组与腔镜组术中出血量[(49±39) mL vs (202±239) mL]、术后引流量[Day 1: (248±123) mL vs (350±213) mL; Day 2: (288±189) mL vs (338±189) mL]比较,机器人组均少于腔镜组(P < 0.05);术后带管时间[(10±5) d vs (11±8) d]及住院时间[(13±6) d vs (14±9) d]两组患者无明显差异(P > 0.05)。机器人组与腔镜组的淋巴结清扫组数[(5±2)组vs(4±2)组]及淋巴清扫数量[(18±9)枚vs(11±8)枚]比较,机器人组均优于腔镜组(P < 0.05)。机器人组与腔镜组生存状况比较[1年生存率:97.3% vs 96%、3年生存率:89.8% vs 83.1%、5年生存率:87.5 % vs 70.3%,平均生存时间(month):61 vs 59],两组无统计学差异(P > 0.05)。无进展生存状况:机器人组与腔镜组比较[1年无进展生存率:93.7% vs 91.3%、3年无进展生存率:87.7% vs 68.4%、5年无进展生存率:87.7% vs 52.5%,平均无进展生存时间(month):61 vs 50],机器人组明显优于腔镜组(P < 0.05)。单因素分析显示,淋巴结清扫数量是患者生存状况的影响因子;肿瘤直径、手术方式、淋巴结清扫组数、淋巴结清扫数量为患者无进展生存状况的影响因子。多因素分析显示生存状况无独立影响因子,肿瘤直径及手术方式为无进展生存状况的独立影响因子。 结论 达芬奇机器人Ⅰ期非小细胞肺癌患者术后生存状况与腔镜手术无差异,但无进展生存状况优于腔镜手术;达芬奇机器人手术淋巴结清扫更彻底,同时术中出血量更少。
Collapse
Affiliation(s)
- Xingchi Liu
- Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China
| | - Shiguang Xu
- Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China
| | - Bo Liu
- Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China
| | - Wei Xu
- Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China
| | - Renquan Ding
- Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China
| | - Tong Wang
- Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China
| | - Bo Li
- Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China
| | - Xilong Wang
- Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China
| | - Qiong Wu
- Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China
| | - Hong Teng
- Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China
| | - Shumin Wang
- Department of Thoracic Surgery, General Hospital of Shenyang Military Command, Shenyang 110016, China
| |
Collapse
|
6
|
Meng D, Zhou Z, Wang Y, Wang L, Lv W, Hu J. Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2016; 50:597-604. [DOI: 10.1093/ejcts/ezw083] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Revised: 02/16/2016] [Accepted: 02/23/2016] [Indexed: 11/14/2022] Open
|
7
|
Systematic mediastinal lymphadenectomy or mediastinal lymph node sampling in patients with pathological stage I NSCLC: a meta-analysis. World J Surg 2014; 39:410-6. [PMID: 25277979 DOI: 10.1007/s00268-014-2804-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND To evaluate the evidence comparing systematic mediastinal lymphadenectomy (SML) and mediastinal lymph node sampling (MLS) in the treatment of pathological stage I NSCLC using meta-analytical techniques. METHODS A literature search was undertaken until January 2014 to identify the comparative studies evaluating 1-, 3-, and 5-year survival rates. The pooled odds ratios (OR) and the 95 % confidence intervals (95 % CI) were calculated with either the fixed or random effect models. RESULTS One RCT study and four retrospective studies were included in our meta-analysis. These studies included a total of 711 patients: 317 treated with SML, and 394 treated with MLS. The SML and the MLS did not demonstrate a significant difference in the 1-year survival rate. There were significant statistical differences between the 3-year (P = 0.03) and 5-year survival rates (P = 0.004), which favored SML. CONCLUSIONS This meta-analysis suggests that in pathological stage I NSCLC, the MLS can get the similar outcome to the SML in terms of 1-year survival rate. However, the SML is superior to MLS in terms of 3- and 5-year survival rates.
Collapse
|
8
|
Baltayiannis N, Chandrinos M, Anagnostopoulos D, Zarogoulidis P, Tsakiridis K, Mpakas A, Machairiotis N, Katsikogiannis N, Kougioumtzi I, Courcoutsakis N, Zarogoulidis K. Lung cancer surgery: an up to date. J Thorac Dis 2014; 5 Suppl 4:S425-39. [PMID: 24102017 DOI: 10.3978/j.issn.2072-1439.2013.09.17] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Accepted: 09/24/2013] [Indexed: 12/25/2022]
Abstract
According to the International Agency for Research on Cancer (IARC) GLOBOCAN World Cancer Report, lung cancer affects more than 1 million people a year worldwide. In Greece according to the 2008 GLOBOCAN report, there were 6,667 cases recorded, 18% of the total incidence of all cancers in the population. Furthermore, there were 6,402 deaths due to lung cancer, 23.5% of all deaths due to cancer. Therefore, in our country, lung cancer is the most common and deadly form of cancer for the male population. The most important prognostic indicator in lung cancer is the extent of disease. The Union Internationale Contre le Cancer (UICC) and the American Joint Committee for Cancer Staging (AJCC) developed the tumour, node, and metastases (TNM) staging system which attempts to define those patients who might be suitable for radical surgery or radical radiotherapy, from the majority, who will only be suitable for palliative measures. Surgery has an important part for the therapy of patients with lung cancer. "Lobectomy is the gold standard treatment". This statement may be challenged in cases of stage Ia cancer or in patients with limited pulmonary function. In these cases an anatomical segmentectomy with lymph node dissection is an acceptable alternative. Chest wall invasion is not a contraindication to resection. En-bloc rib resection and reconstruction is the treatment of choice. N2 disease represents both a spectrum of disease and the interface between surgical and non-surgical treatment of lung cancer Evidence from trials suggests that multizone or unresectable N2 disease should be treated primarily by chemoradiotherapy. There may be a role for surgery if N2 is downstaged to N0 and lobectomy is possible, but pneumonectomy is avoidable. Small cell lung cancer (SCLC) is considered a systemic disease at diagnosis, because the potential for hematogenous and lymphogenic metastases is very high. The efficacy of surgical intervention for SCLC is not clear. Lung cancer resection can be performed using several surgical techniques. Video-assisted thoracoscopic surgery (VATS) lobectomy is a safe, efficient, well accepted and widespread technique among thoracic surgeons. The 5-year survival rate following complete resection of lung cancer is stage dependent. Incomplete resection rarely is useful and cures the patient.
Collapse
|
9
|
Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e278S-e313S. [PMID: 23649443 DOI: 10.1378/chest.12-2359] [Citation(s) in RCA: 887] [Impact Index Per Article: 80.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients with good or low surgical risk is primarily surgical resection. However, this area is undergoing many changes. With a greater prevalence of CT imaging, many lung cancers are being found that are small or constitute primarily ground-glass opacities. Treatment such as sublobar resection and nonsurgical approaches such as stereotactic body radiotherapy (SBRT) are being explored. With the advent of minimally invasive resections, the criteria to classify a patient as too ill to undergo an anatomic lung resection are being redefined. METHODS The writing panel selected topics for review based on clinical relevance to treatment of early-stage lung cancer and the amount and quality of data available for analysis and relative controversy on best approaches in stage I and II NSCLC: general surgical care vs specialist care; sublobar vs lobar surgical approaches to stage I lung cancer; video-assisted thoracic surgery vs open resection; mediastinal lymph node sampling vs lymphadenectomy at the time of surgical resection; the use of radiation therapy, with a focus on SBRT, for primary treatment of early-stage NSCLC in high-risk or medically inoperable patients as well as adjuvant radiation therapy in the sublobar and lobar resection settings; adjuvant chemotherapy for early-stage NSCLC; and the impact of ethnicity, geography, and socioeconomic status on lung cancer survival. Recommendations by the writing committee were based on an evidence-based review of the literature and in accordance with the approach described by the Guidelines Oversight Committee of the American College of Chest Physicians. RESULTS Surgical resection remains the primary and preferred approach to the treatment of stage I and II NSCLC. Lobectomy or greater resection remains the preferred approach to T1b and larger tumors. The use of sublobar resection for T1a tumors and the application of adjuvant radiation therapy in this group are being actively studied in large clinical trials. Every patient should have systematic mediastinal lymph node sampling at the time of curative intent surgical resection, and mediastinal lymphadenectomy can be performed without increased morbidity. Perioperative morbidity and mortality are reduced and long-term survival is improved when surgical resection is performed by a board-certified thoracic surgeon. The use of adjuvant chemotherapy for stage II NSCLC is recommended and has shown benefit. The use of adjuvant radiation or chemotherapy for stage I NSCLC is of unproven benefit. Primary radiation therapy remains the primary curative intent approach for patients who refuse surgical resection or are determined by a multidisciplinary team to be inoperable. There is growing evidence that SBRT provides greater local control than standard radiation therapy for high-risk and medically inoperable patients with NSCLC. The role of ablative therapies in the treatment of high-risk patients with stage I NSCLC is evolving. Radiofrequency ablation, the most studied of the ablative modalities, has been used effectively in medically inoperable patients with small (< 3 cm) peripheral NSCLC that are clinical stage I.
Collapse
Affiliation(s)
- John A Howington
- NorthShore HealthSystem, University of Chicago Pritzker School of Medicine, Evanston, IL.
| | - Matthew G Blum
- Penrose Cardiothoracic Surgery, Memorial Hospital, University of Colorado Health, Colorado Springs, CO
| | | | - Alex A Balekian
- Division of Pulmonary, Critical Care, and Sleep Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA
| | - Sudish C Murthy
- Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH
| |
Collapse
|
10
|
Koulaxouzidis G, Karagkiouzis G, Konstantinou M, Gkiozos I, Syrigos K. Sampling versus systematic full lymphatic dissection in surgical treatment of non-small cell lung cancer. Oncol Rev 2013; 7:e2. [PMID: 25992223 PMCID: PMC4419616 DOI: 10.4081/oncol.2013.e2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2013] [Accepted: 05/16/2013] [Indexed: 11/23/2022] Open
Abstract
The extent of mediastinal lymph node assessment during surgery for non-small cell cancer remains controversial. Different techniques are used, ranging from simple visual inspection of the unopened mediastinum to an extended bilateral lymph node dissection. Furthermore, different terms are used to define these techniques. Sampling is the removal of one or more lymph nodes under the guidance of pre-operative findings. Systematic (full) nodal dissection is the removal of all mediastinal tissue containing the lymph nodes systematically within anatomical landmarks. A Medline search was conducted to identify articles in the English language that addressed the role of mediastinal lymph node resection in the treatment of non-small cell lung cancer. Opinions as to the reasons for favoring full lymphatic dissection include complete resection, improved nodal staging and better local control due to resection of undetected micrometastasis. Arguments against routine full lymphatic dissection are increased morbidity, increase in operative time, and lack of evidence of improved survival. For complete resection of non-small cell lung cancer, many authors recommend a systematic nodal dissection as the standard approach during surgery, and suggest that this provides both adequate nodal staging and guarantees complete resection. Whether extending the lymph node dissection influences survival or recurrence rate is still not known. There are valid arguments in favor in terms not only of an improved local control but also of an improved long-term survival. However, the impact of lymph node dissection on long-term survival should be further assessed by large-scale multicenter randomized trials.
Collapse
Affiliation(s)
| | | | | | - Ioannis Gkiozos
- Oncology Unit GPP, Sotiria General Hospital , Athens, Greece
| | - Konstantinos Syrigos
- Oncology Unit GPP, Sotiria General Hospital , Athens, Greece ; Thoracic Oncology, Yale School of Medicine , New Haven, CT, USA
| |
Collapse
|
11
|
Mediastinal lymph nodes: ignore? sample? dissect? The role of mediastinal node dissection in the surgical management of primary lung cancer. Gen Thorac Cardiovasc Surg 2012; 60:724-34. [PMID: 22875714 DOI: 10.1007/s11748-012-0086-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2011] [Indexed: 10/28/2022]
Abstract
The role of mediastinal lymph node dissection (MLND) during the resection of non-small-cell lung cancer is still unclear although most surgeons agree that a minimum of hilar and mediastinal nodes must be examined for appropriate pathological staging. Current surgical practices vary from visual inspection of the mediastinum with biopsy of only abnormal looking nodes to systematic mediastinal node sampling which is to the biopsy of lymph nodes from multiple levels whether they appear abnormal or not to MLND which involves the systematic removal of all lymph node bearing tissue from multiple sites unilaterally or bilaterally within the mediastinum. This review article looks at the evidence and arguments in favour of lymphadenectomy, including improved pathological staging, better locoregional control, and ultimately longer disease-free survival and those against which are longer operating time, increased operative morbidity, and lack of evidence for survival benefit.
Collapse
|
12
|
Lou W, Zhan X, Xiang X, Guan W. [Effect of VATS wedge resection and mediastinal lymph node sampling in elderly patients with early peripheral lung cancer]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2012; 15:49-51. [PMID: 22237125 PMCID: PMC5999961 DOI: 10.3779/j.issn.1009-3419.2012.01.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
背景与目的 治疗早期非小细胞肺癌首选手术治疗,但最佳的淋巴结清扫范围仍然不清楚。本研究旨在探讨肺楔形切除+纵隔淋巴结采样治疗在早期高龄肺癌患者中的价值。 方法 2004年6月-2008年2月,共有15例70岁以上周围型肺癌患者接受胸腔镜下肺楔形切除术+纵隔淋巴结采样治疗。右侧肺癌行2R、4R、8及9组淋巴结采样,左侧肺癌行5、6、8及9组淋巴结采样。 结果 早期高龄肺癌患者行胸腔镜下肺楔形切除术+淋巴结采样,手术时间短、创伤小,术后并发症少,恢复快。术后1年生存率和3年生存率分别为100%和86.6%。 结论 肺楔形切除术+纵隔淋巴结采样治疗早期高龄周围型肺癌患者是一种选择。
Collapse
Affiliation(s)
- Weihua Lou
- Department of Thoracic Surgery, Yiwu Hospitol of Wenzhou Medical College, Yiwu 322000, China.
| | | | | | | |
Collapse
|
13
|
Gossot D, Girard P, Raynaud C, Stern JB, Caliandro R, Validire P, Debrosse D, Magdeleinat P. Fully endoscopic major pulmonary resection for stage I bronchial carcinoma: initial results. Rev Mal Respir 2011; 28:e123-30. [PMID: 22123151 DOI: 10.1016/j.rmr.2011.09.025] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2009] [Accepted: 06/07/2009] [Indexed: 11/15/2022]
Abstract
INTRODUCTION Several case-series studies of major pulmonary resection (MPR) by video-assisted thoracic surgery (VATS) for non-small-cell lung cancer (NSCLC) have been published, but fully endoscopic MPR is still very rarely performed. Our objective here was to report the outcomes in 71 patients recently managed using fully endoscopic MPR for NSCLC. METHODS From 2007 to 2009, 635 patients with NSCLC underwent MPR (pneumonectomy, lobectomy or segmentectomy). Among them, 71 (11%) had features strongly suggesting clinical stage I NSCLC and were managed by fully endoscopic MPR, with no utility incision. Lobectomy was performed in 63 patients and segmentectomy in eight patients. Conversion to thoracotomy was required in two (2.8%) patients, because of a fused fissure in one and tight pleural adhesions in the other. Radical lymphadenectomy was performed in all patients. RESULTS Of the 69 patients managed endoscopically, none died and none experienced intraoperative complications. Mean operating time was 226±38 minutes (range, 137-307 minutes) and mean intraoperative blood loss was 111±93mL (range, 0-450mL). The final histological examination showed stage I NSCLC in 52 patients, NSCLC with node involvement in nine patients (pN1 in 6 and pN2 in 3) and other types of malignancies in eight patients. Mean number of nodes removed was 21±8 after right-sided lymphadenectomy and 23±8 after left-sided lymphadenectomy and the mean number of dissected node sites was 3 (range, 2-5). The postoperative morbidity rate was 23%. Mean postoperative hospital stay length was 6.9±2 days (range, 3-12). CONCLUSION Fully endoscopic MPR is safe and meets the criteria for oncological surgery.
Collapse
Affiliation(s)
- D Gossot
- Département thoracique, institut mutualiste Montsouris, 42, boulevard Jourdan, 75014 Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
|
15
|
Hu Z, Shen-Tu Y, Ding Z, Tan Q, Zhou Y. [Study on the prognosis of the T1a non-small cell lung cancer]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2010; 13:206-10. [PMID: 20673517 PMCID: PMC6000531 DOI: 10.3779/j.issn.1009-3419.2010.03.04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/24/2009] [Revised: 01/06/2010] [Indexed: 11/24/2022]
Abstract
背景与目的 新的第7版非小细胞肺癌(non-small cell Lung cancer, NSCLC)分期已经提出肿瘤直径对NSCLC预后的重要性,但是对癌灶直径≤2 cm预后研究尚少。本研究旨在探讨影响癌灶≤2 cm(T1a)的Ⅰ期NSCLC病人的临床预后因素,为临床预后治疗提供依据。 方法 回顾性分析本院既往手术后病理诊断为癌灶≤2 cm(T1a)的Ⅰ期的73例NSCLC病人,运用统计学软件SPSS 17.0分析影响长期生存的临床因素。 结果 该类患者5年以上总体生存率达到80.8%。性别(P=0.175)、年龄(P=0.241)、病理类型(P=0.265)、是否行系统纵隔淋巴结清扫手术(P=0.918)、是否术后辅助化疗(P=0.616)、是否侵犯胸膜(P=0.827)和该类患者的长期生存无明显相关性。影响预后的主要因素是癌灶的分化程度,即在中度分化程度以下长期生存较差(P=0.01)。 结论 在癌症直径≤2 cm的Ⅰ期肺癌中,侵犯胸膜对生存无影响,而分化程度是一个重要的独立预后因素。
Collapse
Affiliation(s)
- Zhongwu Hu
- Shanghai Jiao Tong University Medical College, Shanghai Chest Hospital, Shanghai Lung Tumor Clinical Medical Center, Shanghai 200030, China
| | | | | | | | | |
Collapse
|
16
|
[Totally endoscopic major pulmonary resection for stage I bronchial carcinoma: initial results]. Rev Mal Respir 2010; 26:961-70. [PMID: 19953042 DOI: 10.1016/s0761-8425(09)73331-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
INTRODUCTION Several series of video-assisted (VATS) major pulmonary resection (MPR) for non small cell bronchial carcinoma (NSCBC) have been published recently. However, totally endoscopic MPR is still very uncommon. We report the initial results of a recent series of 71 patients. METHODS From 2007 to 2009, 635 patients had a major pulmonary resection (pneumonectomy, lobectomy or segmentectomy) for NSCBC. Seventy-one out of these patients (11%) in whom a clinical stage I NSCBC was strongly suspected were operated on via a totally endoscopic approach, without mini-thoracotomy or utility incision. Sixty-three had a lobectomy and 8 a segmentectomy. There were 2 conversions to thoracotomy (2.8%), for a fused fissure (1 patient) and for tight pleural adhesions (1 patient). The resection was completed by a radical lymphadenectomy in all patients. RESULTS For the 69 patients who had a totally endoscopic procedure, there was no mortality. No intraoperative complications occurred. The mean duration of operation was 226 minutes + or - 38 (range: 137-307 minutes). The mean intraoperative blood loss was 111 cc + or - 93 (range: 0-450 cc). Final pathological examination confirmed stage I NSCBC in 52 patients while 9 NSCBC were upstaged pN1 (n = 6) or pN2 (n = 3). In 8 cases, another type of malignant tumour was found. The mean number of lymph nodes collected was 21 + or - 8 after right-side lymphadenectomy and 23 + or - 8 after left-side lymphadenectomy and the mean number of dissected lymph node stations was 3 (range:2-5). Postoperative morbidity was 23%. The mean postoperative stay was 6.9 days + or - 2 (range: 3-12 days). CONCLUSIONS MPR via a totally endoscopic approach is safe and fulfils the criteria for an oncological resection.
Collapse
|
17
|
Brichkov I, Keller SM. Intraoperative staging and surgical management of stage IIIA/N2 non-small cell lung cancer. Thorac Surg Clin 2008; 18:381-91. [PMID: 19086607 DOI: 10.1016/j.thorsurg.2008.08.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Staging of the mediastinum is an integral component of the operative treatment of NSCLC. Systematic sampling and systematic lymph node dissection provide similar and accurate staging information. Systematic lymph node dissection is more likely to identify multiple levels of N2 disease, however, and may be associated with improved survival. During surgery for a right lung cancer, at least mediastinal lymph node levels 4 should be sampled or dissected. When removing a left lung cancer, at least nodal levels 5 and 7 should be assessed. Although every effort should be made to identify N2 disease before surgery, if intraoperative metastases to mediastinal lymph nodes are discovered, the planned operation should proceed. Cisplatin-based adjuvant chemotherapy has moderate but proven survival benefit after resection of N2 disease. The role of PORT remains uncertain.
Collapse
Affiliation(s)
- Igor Brichkov
- Department of Cardiothoracic Surgery, Division of Thoracic Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, 3400 Bainbridge Avenue - 5th floor, Bronx, NY 10467, USA
| | | |
Collapse
|